molecular targeting drugs for treatment of lung cancer patientsPrevention of adverse skin reactions and their care
Abstract
SelectEarSt2014year42015year4month period medicalHouseadmissionof lung cancerexample,tohavesufferfrom all accept molecular sacrificial drugsobjectsgoverningtherapy,by different caremethod divides patients into study Group and controlGroup,30-if•;where control group patients givetoroutine careapply,Research group Patientson theTand on the basis of newZealand treatment to totargeted care interventionsshi,Compare two groups of patients after treatment caused by skin notgoodrate of occurrence,•knotFruit:Study Group patientsElevelskin Adverse reactionssendLive rate to13.33%significantly belowtoIndra,Kingandto30.00%;ElevelasentenceThe incidence of inflammationto3.%Beansbelowcontrol group26.67% (p< 0.05)powerknottheory:SubsubearlyAdverse skin reactions to patients with lung cancer treated with drugs,should take targeted prevention and care measuresapply,Reduce skin undesirablereaction to occurstroke,relieve patient pain,improve compliance with treatmentsex,branchgood match againstmonthmediumpainruleTherapy,improve the quality of volunteersQuantityF
References
MountainLi Tian fungus,Fang Zhihong.Common adverse reactions in targeted therapy of lung cancer and Traditional Chinese and western medicine
| rule[J].HyundaiWestMedicalbindingclosemagazine,2015,():1361-1365.
XuRed.Iressaminuteschildtargeted therapy for advanced lung cancer against skin adverseshould
observation and care [a fewMaskAncientMedicalMedicine,2012,31 (a):163.
LeeYan,CaiLotus,Zhang isli,,and so on.Molecular targeting of drugs for the treatment of lung cancer toskinSkin not good response of TCM nursing [earPro4-Rough,BattalionJ.Process,14,(4):503-504.
King clean.attach importance to skin side effects associated with epidermal growth factor receptor inhibitors
[Ting, Chinese medicineLearnForum.jl,2008,110ll4):ten.
leafGreenLing,BeamYiSubchildtargeted drug treatment of lung cancer with no good response preventionand care[J].Henan foreignSectionlearnmiscellaneouslog,2014,20(Yue:141-142.
(Receipt dateI:2015-05-28Repair Date:2015-06-20)
(Executive Editor: Dinglongits)
Notecompared to control group ('P<0.05)<·
discussion
In recent years, molecular targeting drugs for the treatment of lung cancer patients as
Copyright (c) 2015 Yang Maijie
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to this journal agree to publish their articles under the Creative Commons Attribution-Noncommercial 4.0 International License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, that the work is not used for commercial purposes, and that in the event of reuse or distribution, the terms of this license are made clear. With this license, the authors hold the copyright without restrictions and are allowed to retain publishing rights without restrictions as long as this journal is the original publisher of the articles.
